Bruera E, Ripamonti C: Dyspnea in patients with advanced cancer. In Berger A (ed.): Principles and Practice of Supportive Oncology. Philadelphia, Lippincott-Raven Publishers, 1998; 295-308.
2.
Dudgeon D, Rosenthal S: Management of dyspnea and cough in patients with cancer. Hematology-Oncology Clinics of North America. 1996;10(1):157-171.
3.
Bruera E, Macmillan K, Pither J, et al: Effects of morphine on the dyspnea of terminal cancer patients. Journal of Pain and Symptom Management. 1990: 5(6): 341-344.
4.
Cohen MH, Johnston A, Krasnow SH, et al: Continuous intravenous infusion of morphine for severe dyspnea. Southern Medical Journal. 1991;84(2): 229-234.
5.
Woodcock AA, Gross ER, Gellert A, et al: Effects of dihydrocodeine, alcohol and caffeine on obstructive lung disease and normal blood gases. N Engl J Med. 1981;305:1611-1616.
6.
Light R, Muro J, Sato R, et al: Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139:126-133.
7.
Conno F de, Spoldi D, Caraceni A, et al: Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients?Palliative Medicine. 1991;5:237-243.
8.
Cowcher K, Hanks G: Long-term management of respiratory symptoms in advanced cancer. J Pain Symptom Manage. 1990;5:320-330.
9.
Roger DF, Barnes PG: Opioid inhibition of neurally medicated mucous secretions in human bronchi. Lancet. 1989;I:930-931.
10.
Tooms A, McKenzie A, Grey H: Nebulised morphine. Lancet. 1993;342:1123-1124.
11.
Farncombe M, Chater S, Gillin A: The use of nebulized opioids for breathlessness: A chart review. Palliative Medicine. 1994;8:306-312.
12.
Davis CL: The use of nebulized opioids for breathlessness. Palliative Medicine. 1995;9(2): 169-170.
13.
MacLeod RD, King BJ: Relieving breathlessness with nebulized morphine. Palliative Medicine. 1995;9:169-170.
14.
Davis CL, Hodder CA, Love S, et al: Effect of nebulised morphine and morphine 6-glucuronide on exercise endurance in patients with chronic obstructive airways disease. Thorax. 1994;49(4): 393.
15.
Davis CL, Penn K, A’Hern R, et al: Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness. Palliative Medicine. 1996;10:64-65.
16.
Masood AR, Subhan MMF, Reed JW, et al: Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy men. Clin Sci. 1995;88:447-452.
17.
Masood AR, Reed JW, Thomas SHL: Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995;50:629-634.
18.
Noseda A, Carpiaux JP, Markstein C, et al: Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997: 10:1079-1083.
19.
Harris-Eze AO, Sridhar G, Clemens E, et al: Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995;152:1940-1945.
20.
Masood Ar, Thomas SHL: Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996;41:250-252.
21.
Chrubasik J, Wust H, Friedrich G, et al: Absorption and bioavailability of nebulized morphine. Br J Anaesth. 1988;61:228-230.
22.
Ward ME, Woodhouse A, Mather LE, et al: Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clinical Pharmacology & Therapeutics. 1997;62:596-609.
23.
Quelch PC, Faulkner DE, Yun JW: Nebulized opioids in the treatment of dyspnea. Journal of Palliative Care. 1997;13(3): 48-52.
24.
Hughes S, Calverley PMA: Heroin inhalation and asthma. Br Med J. 1988;297:1511-1512.
